Is the battle over bevacizumab coverage looming?

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 9, Issue 3, 2011, Pages 261-263

  Larkin, Catherine ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADVANCED CANCER; BREAST CANCER; CLINICAL DECISION MAKING; COLORECTAL CANCER; DRUG APPROVAL; DRUG INDICATION; FOOD AND DRUG ADMINISTRATION; GLIOBLASTOMA; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; KIDNEY CANCER; LUNG CANCER; NOTE; UNITED STATES;

EID: 79952680098     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2011.0024     Document Type: Note

References (6)

1. Kottle ML, Reed K. Genentech's Avastin colon cancer drug wins approval. Bloomberg News. February 26, 2004.
2. Roche Business Report 2010: Pharmaceuticals. Roche Web site. Available at: http://www.roche.com/investors/annual-reports.htm. Accessed February 2, 2011.
3. FDA Media Call: Recommendation to remove Avastin indication for metastatic breast cancer. U.S. Food and Drug Administration Web site. December 16, 2010. Available at: http://www.fda.gov/ downloads/NewsEvents/Newsroom/ MediaTranscripts/UCM237450.pdf. Accessed February 4, 2011.
4. UnitedHealthcare becomes first company to base chemotherapy drug coverage on National Comprehensive Cancer Network Compendium. Business Wire. January 16, 2008.
5. About NCCN: Breast Cancer Panel. National Comprehensive Cancer Network Web site. Available at: http://www.nccn.org/disclosures/panel-list.asp?ID=53. Accessed January 28, 2011.
6. Submission of Genentech Inc. in response to the Food and Drug Administration's Notice of Opportunity for a Hearing and proposal to withdraw approval of Avastin (bevacizumab) in combination with weekly paclitaxel for the first-line treatment of patients with metastatic breast cancer. Docket No. FDA-2010-N-0621. Genentech, Inc. Web site. Available at: http://www.gene. com/gene/news/news-events/avastin/documents/NOOH-Prim-Sub-Doc-FINAL-16JAN2011. pdf. Accessed January 28, 2011.